ADVERTISEMENT

Clinical Summary

Non-small cell lung cancer: FDA approves tremelimumab in combination with another immunotherapy

Miriam Davis, PhD   |   24 November 2022

Takeaway

  • The US FDA approved tremelimumab (an anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody) for metastatic NSCLC to be given together with another immunotherapy, durvalumab (an anti-programmed cell death-ligand 1 antibody) and platinum-based chemotherapy.
  • The patients with NSCLC have no sensitising epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumour alterations.

Why this...

          

Topic Challenges

left
right